Finch Therapeutics

$8.56 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Finch Therapeutics

Finch Therapeutics Group, Inc. is a clinical-stage microbiome therapeutics company. The Company leveraging Human-First Discovery platform to develop a class of orally administered biological drugs. It is developing therapeutics designed to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. The Company’s Human-First Discovery platform uses reverse translation to identify diseases of dysbiosis and to design microbiome therapeutics that address them. Its lead product candidate, CP101, delivers a complete microbiome and is being developed initially for the treatment of patients with recurrent Clostridioides difficile infection (CDI). It is also advancing CP101 for the treatment of chronic hepatitis B virus (HBV) Its product pipeline includes FIN-524, FIN-525, and FIN-211.

Stock Analysis

last close $8.56
1-mo return -20.7%
3-mo return -34.4%
avg daily vol. 38.36T
52-week high 22.5
52-week low 7.29
market cap. $398M
forward pe -
annual div. -
roe -
ltg forecast -
dividend yield -
annual rev. $10M
inst own. 17.3%
baraka

Subscribe now for daily local and international financial news

Subscribe